Data gathered: November 27
AI Stock Analysis - Tonix Pharmaceuticals (TNXP)
Analysis generated November 24, 2024. Powered by Chat GPT.
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing innovative pharmaceutical products to address major unmet medical needs. The company's portfolio includes candidates for central nervous system (CNS) disorders, rare diseases, oncology, and infectious diseases. As a market player in the healthcare sector, Tonix is committed to advancing its portfolio through clinical trials, regulatory approval processes, and eventual market introduction.
Stock Alerts - Tonix Pharmaceuticals (TNXP)
 |
Tonix Pharmaceuticals | November 25 Price is up by 5.6% in the last 24h. |
|
Tonix Pharmaceuticals | November 22 Price is down by -5.2% in the last 24h. |
|
Tonix Pharmaceuticals | November 21 Price is down by -6% in the last 24h. |
|
Tonix Pharmaceuticals | November 20 Price is up by 60.9% in the last 24h. |
Alternative Data for Tonix Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Google Trends | 13 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 5 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,697 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 82 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 73,174 | Sign up | Sign up | Sign up |
| Twitter Followers | 7,065 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 93 | Sign up | Sign up | Sign up |
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.
| Price | $0.19 |
| Target Price | Sign up |
| Volume | 19,600,000 |
| Market Cap | $36M |
| Year Range | $0.13 - $11.07 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor ConferenceNovember 25 - Yahoo |
 |
StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)November 24 - ETF Daily News |
Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Research Report 2024: Comprehensive Insights on 8+ Drugs Featuring Tonix Pharmaceuticals, BMS, WinSanTor, and ApnimedNovember 21 - GlobeNewswire |
|
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit VirtualNovember 18 - GlobeNewswire |
|
 |
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual MeetingNovember 18 - Investing.com |
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral TreatmentsNovember 13 - Yahoo |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.8M | 1.6M | 1.3M | -14M | -15M | -0.229 |
| Q2 '24 | 2.2M | 3.4M | -1.2M | -79M | -76M | -19.280 |
| Q1 '24 | 9.5M | 1.7M | 7.8M | -15M | -20M | -0.180 |
| Q4 '23 | 3.6M | 2.4M | 1.3M | -27M | -26M | -0.860 |
| Q3 '23 | 4M | 2.4M | 1.6M | -28M | -27M | -1.830 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Tonix Pharmaceuticals (TNXP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Tonix Pharmaceuticals?
The Market Cap of Tonix Pharmaceuticals is $36M.
What is the current stock price of Tonix Pharmaceuticals?
Currently, the price of one share of Tonix Pharmaceuticals stock is $0.19.
How can I analyze the TNXP stock price chart for investment decisions?
The TNXP stock price chart above provides a comprehensive visual representation of Tonix Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tonix Pharmaceuticals shares. Our platform offers an up-to-date TNXP stock price chart, along with technical data analysis and alternative data insights.
Does TNXP offer dividends to its shareholders?
As of our latest update, Tonix Pharmaceuticals (TNXP) does not offer dividends to its shareholders. Investors interested in Tonix Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tonix Pharmaceuticals?
Some of the similar stocks of Tonix Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.